SRRK: Bull Flag detected on 8 Jul 2026

A bull flag pattern with structure score of 14.1/15, volume score 12.0/12, and breakout score 10.6/13. The stock trades at $56.56, pinned just below key resistance at $56.54 while maintaining support at $51.32 — a 5.2% cushion below current price. The flag consolidation follows a powerful 24.77% monthly rally. MACD histogram at 0.6459 and Bollinger Band position at 0.858 indicate sustained upside momentum. Overall setup scores 76.7/98 with 72.89% historical win probability, signaling a near-term breakout structure with quality above-average metrics.

Scholar Rock achieved a critical regulatory milestone: FDA accepted the apitegromab Biologics License Application (BLA) with September 30, 2026 PDUFA action date. The BLA covers two U.S. fill-finish sites, with the second facility on track to supply commercial product in early Q3 2026. Barclays and Citi maintain Buy ratings. Q1 2026 reported larger net loss tied to launch readiness investments, but company maintains $479.9 million in cash. European CHMP opinion anticipated near mid-2026. The biotech healthcare sector displays bullish regime (score 0.83) providing tailwind, though broader market sits in bearish regime (-0.33). Recent insider selling by CEO Hallal in April suggests caution.

Successful breakout above $56.54 resistance targets $58.43 conservative measured move, with potential for continued advance through $60+ technical levels given sector momentum. Volume confirmation remains critical — current 1.14M shares trails 20-day average of 1.87M, suggesting traders await catalyst-driven breakout. Historical setup scores indicate 72.89% win probability on successful breakouts. Pattern invalidates decisively below $51.32 support. PDUFA action date September 30, 2026 represents primary catalyst window aligning with flag timeframe.

RSI at 70.22 signals overbought conditions—breakout may face resistance above current levels. CEO David Hallal sold 31k shares (7.1% of direct holdings) in April at $49.57, largest insider sale in three months—a bearish signal despite regulatory progress. Volume ratio 0.61x average indicates reduced conviction; flag may lack follow-through. Earnings date estimated August 4, 2026—precedes PDUFA decision by two months, creating near-term uncertainty. Biotech sector carries binary event risk; any FDA setback or manufacturing facility issues could trigger sharp reversal. Beta 0.64 provides modest downside protection, but regulatory-dependent name remains high-risk despite technical setup quality.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.